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The predicted impact and cost- effectiveness of 
systematic testing of people with incident colorectal 
cancer for Lynch syndrome
Yoon-Jung Kang1 , James Killen1, Michael Caruana1, Kate Simms1, Natalie Taylor1, Ian M Frayling2,3, Tristan Snowsill4,  
Nicola Huxley5, Veerle MH Coupe6, Suzanne Hughes1, Victoria Freeman1, Alex Boussioutas7,8, Alison H Trainer9, Robyn L Ward10,11, 
Gillian Mitchell9, Finlay A Macrae8, Karen Canfell1,10,11
Lynch syndrome (LS), or hereditary non- polyposis colorec-tal cancer, is an autosomal dominant cancer susceptibility  disorder caused by constitutional mutations in four DNA 
mismatch repair (MMR) genes, MLH1, MSH2, MSH6, and 
PMS2.1 LS is associated with increased risk of developing a 
range of cancers, particularly colorectal cancer (CRC).1 Patients 
with CRC tumours exhibiting MMR deficiency (dMMR) but 
not the somatic BRAF V600E mutation or hypermethylation of 
the MLH1 promoter can be referred for germline genetic tests 
for LS.2 If LS is confirmed, cascade germline genetic testing can 
be made available to at- risk relatives, and a range of cancer risk 
management options, including colonoscopic surveillance and 
prophylactic surgery, can be offered to reduce the morbidity 
and mortality associated with the syndrome.3
In some countries, including the United Kingdom,4 routine test-
ing for LS is recommended for patients with incident CRC. In 
Australia, there is no national LS testing policy and the availabil-
ity and practice of testing varies between clinicians, pathology 
providers, and states and territories.5 The most recent clinical 
CRC management practice guidelines encourage dMMR tumour 
testing for all patients with CRC as a “practice point” (a recom-
mendation based on expert opinion and formulated in a consen-
sus process).6 The Royal College of Pathologists of Australasia 
recently submitted an application to the Medical Services 
Advisory Committee requesting funding of germline gene panel 
testing for heritable mutations associated with increased risk of 
CRC and endometrial cancer; the panel of 11 genes includes the 
four MMR genes and the epithelial cell adhesion molecule gene 
(EPCAM).7 Two recent economic evaluations in Australia found 
that routine LS testing of people with incident CRC can be cost- 
effective.7,8 However, no published assessment of systematic LS 
testing in Australia has taken into account all feasible combina-
tions of relevant testing and triage options, including those for 
somatic mutation testing after dMMR immunohistochemistry 
or microsatellite instability testing.
A comprehensive evaluation of all relevant testing and triage op-
tions, including all benefits to probands and family members as 
well as the downstream cost benefits related to cancer prevention, 
would be appropriate. We therefore evaluated the health impact 
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Abstract
Objectives: To evaluate the health impact and cost- effectiveness 
of systematic testing for Lynch syndrome (LS) in people with 
incident colorectal cancer (CRC) in Australia.
Design, setting, participants: We investigated the impact of 
LS testing strategies in a micro- simulation model (Policy1–Lynch), 
explicitly modelling the cost of testing all patients diagnosed with 
incident CRC during 2017, with detailed modelling of outcomes 
for patients identified as LS carriers (probands) and their at- risk 
relatives throughout their lifetimes. For people with confirmed LS, 
we modelled ongoing colonoscopic surveillance.
Main outcome measures: Cost- effectiveness of six universal 
tumour testing strategies (testing for DNA mismatch repair 
deficiencies) and of universal germline gene panel testing of 
patients with incident CRC; impact on cost- effectiveness of 
restricting testing by age at CRC diagnosis (all ages, under 50/60/70 
years) and of colonoscopic surveillance interval (one, two years).
Results: The cost- effectiveness ratio of universal tumour testing 
strategies (annual colonoscopic surveillance, no testing age limit) 
compared with no testing ranged from $28 915 to $31 904/life- year 
saved (LYS) (indicative willingness- to- pay threshold: $30 000–
$50 000/LYS). These strategies could avert 184–189 CRC deaths 
with an additional 30 597–31 084 colonoscopies over the lifetimes 
of 1000 patients with incident CRC with LS and 1420 confirmed LS 
carrier relatives (164–166 additional colonoscopies/death averted). 
The most cost- effective strategy was immunohistochemistry and 
BRAF V600E testing (incremental cost- effectiveness ratio [ICER], 
$28 915/LYS). Universal germline gene panel testing was not cost- 
effective compared with universal tumour testing strategies (ICER, 
$2.4 million/LYS). Immunohistochemistry and BRAF V600E testing 
was cost- effective at all age limits when paired with 2- yearly 
colonoscopic surveillance (ICER, $11 525–$32 153/LYS), and required 
4778–15 860 additional colonoscopies to avert 46–181 CRC deaths 
(88–103 additional colonoscopies/death averted).
Conclusions: Universal tumour testing strategies for guiding 
germline genetic testing of people with incident CRC for LS in 
Australia are likely to be cost- effective compared with no testing. 
Universal germline gene panel testing would not currently be 
cost- effective.
The known: Testing people with colorectal cancer for Lynch 
syndrome has been found to be cost- effective in some developed 
countries.
The new: In the first Australian cost- effectiveness evaluation of 
systematic testing for Lynch syndrome in people with incident 
colorectal cancer that included all feasible combinations of 
relevant testing and triage options, the cost- effectiveness ratios 
for universal tumour testing strategies for identifying mismatch 
repair deficiency (dMMR), compared with not testing, were 
similar. Universal gene panel testing was not cost- effective 
compared with universal tumour testing strategies.
The implications: Our analysis supports routine dMMR tumour 
testing of people with incident colorectal cancer for guiding 
genetic testing for Lynch syndrome.
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and cost- effectiveness of systematic testing of people with inci-
dent CRC for LS, with the aim of providing evidence that could 
inform a national LS testing policy. Our specific aims were to de-
termine the most cost- effective LS testing strategy for people with 
incident CRC, and to estimate the health and economic impacts of 
limiting testing to specific CRC diagnosis age ranges and of differ-
ent colonoscopic surveillance intervals for confirmed LS carriers.
Methods
We investigated the impact of various LS testing strategies in a 
micro- simulation model (Policy1–Lynch; Supporting Information, 
section 1). We explicitly modelled the cost of testing all patients 
diagnosed with CRC during 2017, with detailed modelling of 
outcomes for patients identified as LS carriers (probands) and 
their at- risk relatives throughout their lifetimes (censored at 100 
years) (Box 1, Box 2; for detailed clinical management pathways: 
Supporting Information, section 2). For confirmed cases of LS 
(probands and relatives), we modelled ongoing colonoscopic 
surveillance. The detailed assumptions and parameter values 
are provided in the online Supporting Information, sections 3–8.
Analysis
We performed the analysis in three stages. In Stage 1 (base-
line), eight testing strategies were examined (Supporting 
Information, section 2): no testing (as comparator, strategy 
1); universal dMMR tumour testing (immunohistochemistry 
or microsatellite instability testing) with or without somatic 
BRAF V600E or MLH1 promoter methylation testing, followed 
by germline gene panel testing for confirmation of LS (strate-
gies 2–7); and universal germline gene panel testing (strategy 
8). We assumed that all patients diagnosed with CRC in 2017 
would be tested for LS (ie, no age limit) and that confirmed 
LS carriers (probands and relatives) undertake annual colono-
scopic surveillance until age 70.9
In Stage 2, we further investigated the impact of key parameters 
in an exploratory analysis of both the most cost- effective strategy 
in Stage 1 and the universal germline gene panel testing strat-
egy. We specifically modelled the effects on cost- effectiveness 
of the CRC diagnosis ceiling age for LS testing (cancers dia-
gnosed before 50, 60 or 70 years of age, or no age limit), and of 
the colonoscopic surveillance interval (one or two years). We also 
performed a supplementary analysis in which the colonoscopic 
surveillance adherence rate was reduced from 80% to 70% for all 
Stage 2 strategies.
In Stage 3, we performed a series of one- way sensitivity analyses to 
investigate the effects of key parameters on the cost- effectiveness 
of the most cost- effective testing strategy identified in Stage 1 and 
the universal gene panel testing strategy.
Assumptions regarding the natural history of colorectal 
cancer in patients with Lynch syndrome and the effect of 
colonoscopic surveillance
We adopted a similar approach to that applied by the UK Health 
Technology Assessment report, using published parameters for 
developing our natural history model.10,11 Briefly, CRC develop-
ment in LS carriers was modelled as cumulative CRC risk, with 
and without colonoscopic surveillance, for incident CRC and 
for second CRC in treated individuals.12–14 CRC incidence rates 
for people without LS in 2017 were based on 2014 Australian 
population- based sex- and age- specific CRC incidence (the most 
recent available data at the time of analysis).15 We assumed that 
an individual could develop up to two CRCs during their life-
time (ie, up to one metachronous CRC).
In Stage 1 and 2 analyses, we assumed that colonoscopic sur-
veillance (with polypectomy if required) reduces the incidence 
of CRC and also downstages a proportion of the cancers not 
prevented. The estimated hazard ratio (HR) for first CRC in LS 
carriers undergoing 2- or 3- yearly colonoscopic surveillance (v 
no surveillance) was 0.387,10–12 for those undergoing annual sur-
veillance it was assumed to be 0.3. We analysed stage- specific 
CRC 5- year survival for people with CRC.16,17 Overall population 
life tables were used for calculating mortality from other causes 
(Supporting Information, section 4).
Assumptions regarding diagnostic test accuracy and referral 
adherence
Pooled estimates of sensitivity and specificity for MMR immuno-
histochemistry and microsatellite instability testing were used.11 
The sensitivity and specificity of gene panel testing were each as-
sumed to be 100%.18 We did not explicitly model colonoscopy test 
characteristics, as the reduction in CRC incidence associated with 
regular colonoscopic surveillance already captured the sensitiv-
ity and specificity of colonoscopy as part of the overall effective-
ness of surveillance (Supporting Information, section 5). We also 
assumed all patients with CRC are tested for dMMR in strate-
gies 2–7 and 90% consent to gene panel testing in strategies 2–8. 
We assumed that 78% of relatives attended genetic counselling,19 
and that 77% of those attending consented to predictive genetic 
testing.19 We also assumed that the initial uptake of colonoscopic 
surveillance by probands and relatives was 90% and that the an-
nual adherence rate was 80% (Supporting Information, section 6).
Assumptions regarding the family composition model
We assumed that each LS proband has a mean of six relatives 
eligible for cascade testing (equal numbers of children, sib-
lings, and siblings’ children), of whom 1.42 are found to be LS 
1 Testing strategies to identify Lynch syndrome mutation 
carriers among people diagnosed with incident colorectal 
cancer (probands)
Strategy 1. No testing (comparator).
Strategy 2. DNA mismatch repair (dMMR) immunohistochemistry (IHC) four-
panel test  diagnostic germline gene panel testing if IHC result is ab-
normal (absence of staining [= loss of expression] for MLH1/MSH2/MSH6/
PMS2 proteins).
Strategy 3. dMMR IHC four-panel test  somatic BRAF V600E testing if IHC 
result for MLH1 is abnormal  diagnostic germline gene panel testing if 
somatic BRAF V600E test result is negative.
Strategy 4. dMMR IHC four-panel test  somatic MLH1 promoter hypermeth-
ylation testing if IHC result for MLH1 is abnormal  diagnostic germline 
gene panel testing if somatic methylation test result is negative.
Strategy 5. Molecular dMMR microsatellite instability (MSI) test  diagnostic 
germline gene panel testing if MSI result is abnormal (ie, high instability = 
MSI-H).
Strategy 6. Molecular dMMR MSI test  somatic BRAF V600E testing if MSI 
result is abnormal  diagnostic germline gene panel testing if somatic 
BRAF V600E test result is negative.
Strategy 7. Molecular dMMR MSI test  somatic MLH1 promoter hypermeth-
ylation testing if MSI result is abnormal  diagnostic germline gene panel 
testing if somatic methylation test result is negative.
Strategy 8. Universal germline gene panel testing in all CRC cases.
Only people confirmed to be LS carriers by diagnostic germline gene panel 
testing are referred for annual colonoscopic surveillance:
• Probands undertake annual colonoscopic surveillance from colorectal dia-
gnosis until age 70 years
• Relatives undertake annual colonoscopic surveillance from age 25 (or from 
the age when Lynch syndrome was confirmed) until age 70 years
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carriers after predictive genetic testing. This number was esti-
mated by multiplying the number of eligible relatives (six) by 
the proband’s referral rate for relatives (0.90) and the relatives’ 
adherence rates to genetic counselling (0.78) and predictive ge-
netic testing (0.77), and by the expected proportion of relatives 
with LS (44%) (Supporting Information, section 7).11
Assumptions regarding costs, utilities, and health economic 
parameters
We conducted the analysis from the perspective of the health 
care provider (Medicare), and included costs (2017 prices in 
Australian dollars) for testing, diagnosis, surveillance, and 
treatment procedures (Supporting Information, section 8). A 
discount rate of 5% was applied to both costs and health out-
comes, and we assumed that a strategy was cost- effective com-
pared with no testing if the indicative willingness- to- pay was 
lower than $30  000–$50  000 per life- year saved (LYS).20,21 We 
did not calculate quality- adjusted life- years (QALYs) because the 
available data were insufficient for informing utility weights for 
testing, diagnostic confirmation, predictive testing of relatives, 
and subsequent sequelae for surveillance. An incremental cost- 
effectiveness ratio (ICER) was calculated in Stage 1 to determine 
which strategy was most cost- effective.
Estimation of cost- effectiveness compared with no testing 
strategy
We explicitly modelled the cost of testing all patients diagnosed 
with CRC in 2017, based on 2014 Australian population- based 
sex- and age- specific CRC incidence (the most recent available 
data)14 and the prevalence of LS carriers among patients with in-
cident CRC. We simulated the lifetimes of one million patients 
with CRC and LS in each 5- year age group and their at- risk rela-
tives, assuming the mean number of at- risk relatives confirmed 
to have LS followed by predictive genetic testing to be 1.42 per 
proband. Aggregated health and resource outcomes for LS test-
ing strategies for the cohort of LS carriers identified in 2017 are 
reported as numbers per 2420 LS carriers (1000 patients with 
CRC with LS and their 1420 relatives with confirmed LS) over 
their lifetimes (to 100 years).
Ethics approval
Ethics approval was not required for our modelled simulation 
based on publicly available aggregated data.
Results
In the Stage 1 (baseline) analysis, the cost- effectiveness of strate-
gies involving dMMR testing of CRC patients (strategies 2–7), 
compared with no testing, ranged between $28 915/LYS (strat-
egy 3) and $31 904/LYS (strategy 5) (Box 3 ; Box 4, A). The most 
cost- effective strategy — immunohistochemistry and reflex 
BRAF V600E testing followed by gene panel testing to confirm 
LS (strategy 3) — would require an additional 30 995 colonosco-
pies over the lifetimes of 2420 LS carriers and would avert 189 
CRC deaths (164 extra colonoscopies to avert one CRC death) 
(Box 5). The discounted costs for immunohistochemistry with 
2 Flow chart of testing and management strategies for Lynch syndrome (LS) probands and relatives
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BRAF V600E testing are $10 645 per LS proband identified and 
$7044 including both proband and identified LS- positive rela-
tives (detailed results not shown). Compared with immunohis-
tochemistry, universal germline gene panel testing would avert 
a further three deaths over the lifetimes of 2420 LS carriers, but 
its ICER ($2 411 933/LYS;  Box 3) means that this strategy would 
not be cost- effective compared with the dMMR tumour testing 
strategies.
In the Stage 2 analysis, the most cost- effective testing strategy 
was MMR immunohistochemistry and reflex BRAF V600E test-
ing, with 2- yearly colonoscopic surveillance of confirmed LS 
carriers. The estimated ICERs were $11 525/LYS (age limit, < 50 
years), $11 711/LYS (age limit, < 60 years), $12 106/LYS (age limit, 
< 70 years), and $32 153/LYS (no age limit), with more life- years 
saved at increased cost as the age cut- off is eased (Box 3 ; Box 4, B). 
An additional 4778–15 860 colonoscopies would be required over 
the lifetimes of 2420 LS carriers, and 46–181 CRC deaths would 
be averted (88–103 extra colonoscopies per averted CRC death) 
(Box 5). Universal germline gene panel testing with 2- yearly sur-
veillance would avert up to three more CRC deaths, but would 
not be as cost- effective as universal dMMR tumour testing strat-
egies. The ICER for universal gene panel testing strategy with-
out age limit and annual colonoscopic surveillance (strategy 8) 
was $1  951  947/LYS. Reducing the colonoscopic surveillance 
adherence rate to 70% slightly reduced the cost- effectiveness 
of these testing strategies, but the ranking of strategies by cost- 
effectiveness remained the same; the ICER for immunohisto-
chemistry/BRAF V600E testing ranged between $12  722/LYS 
and $37 858/LYS (Supporting Information, section 9).
3 Health economic outcomes associated with testing people with incident colorectal cancer (CRC) diagnosed in Australia during 2017 
for Lynch syndrome (LS), compared with no testing (per 1000 people with incident CRC with LS and 1420 relatives with confirmed 
LS)
Testing strategy (age range for testing;  
colonoscopic surveillance interval)
Discounted 
costs*
Discounted life- 
years saved (LYS)*
Cost- effectiveness 
ratio:  
testing v no testing†
Incremental cost- 
effectiveness ratio 
(ICER)‡
Stage 1 analysis
1. No testing $12 640 14.0917 — —
7. MSI + MLH1 methylation (no age limit; 1 year) $19 145 14.3061 $30 338/LYS Dominated
6. MSI + BRAF V600E (no age limit; 1 year) $19 130 14.3079 $30 020/LYS Dominated
5. MSI (no age limit; 1 year) $19 646 14.3113 $31 904/LYS Dominated
4. IHC + MLH1 methylation (no age limit; 1 year) $19 075 14.3121 $29 196/LYS Dominated
3. IHC + BRAF V600E (no age limit; 1 year) $19 068 14.3140 $28 915/LYS $28 915/LYS
2. IHC (no age limit; 1 year) $19 249 14.3148 $29 625/LYS $227 000/LYS
8. Universal gene panel testing (no age limit; 1 year) $26 485 14.3178 $61 235/LYS $2 411 933/LYS
Stage 2 analysis
1. No testing $12 640 14.0917 — —
3.3. IHC + BRAF V600E (< 50 years; 2 years) $13 244 14.1441 $11 525/LYS $11 525/LYS
3.2. IHC + BRAF V600E (< 50 years; 1 year) $14 056 14.1451 $26 507/LYS Dominated
8.3. Universal gene panel testing (< 50 years; 2 years) $13 746 14.1453 $20 632/LYS Dominated
8.2. Universal gene panel testing (< 50 years; 1 year) $14 566 14.1461 $35 397/LYS Dominated
3.5. IHC + BRAF V600E (< 60 years; 2 years) $14 155 14.2219 $11 636/LYS $11 711/LYS
8.5. Universal gene panel testing (< 60 years; 2 years) $15 989 14.2246 $25 199/LYS Dominated
3.4. IHC + BRAF V600E (< 60 years; 1 year) $16 261 14.2263 $26 898/LYS Dominated
8.4. Universal gene panel testing (< 60 years; 1 year) $18 131 14.2290 $39 992/LYS Dominated
3.7. IHC + BRAF V600E (< 70 years; 2 years) $14 832 14.2778 $11 777/LYS $12 106/LYS
8.7. Universal gene panel testing (< 70 years; 2 years) $18 404 14.2815 $30 369/LYS Dominated
3.6. IHC + BRAF V600E (< 70 years; 1 year) $17 803 14.2845 $26 776/LYS Dominated
8.6. Universal gene panel testing (< 70 years; 1 year) $21 424 14.2883 $44 681/LYS Dominated
3.1. IHC + BRAF V600E (no age limit; 2 years) $15 735 14.3059 $14 450/LYS $32 153/LYS
8.1. Universal gene panel testing (no age limit; 2 years) $23 101 14.3101 $47 899/LYS Dominated
3. IHC + BRAF V600E (no age limit; 1 year) $19 068 14.3140 $28 915/LYS $411 432/LYS
8. Universal gene panel testing (no age limit; 1 year) $26 485 14.3178 $61 235/LYS $1 951 947/LYS
IHC = immunohistochemistry; MSI = microsatellite instability. * Costs and life- years are each discounted by 5%. † Difference in costs divided by difference in LYS for strategy v no testing. 
‡ Relative to the next most cost- effective strategy. “Dominated” indicates that a strategy has either higher costs or a higher cost per LYS than a more effective strategy. ◆
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4 Discounted costs and numbers of life- years saved associated with testing people with incident colorectal cancer (CRC) diagnosed in 
Australia during 2017 for Lynch syndrome (LS)
IHC = immunohistochemistry; MSI = microsatellite instability; ICER = incremental cost- effectiveness ratio; LYS = life- year saved. Strategies not on the dotted line are dominated; that is, thy 
have either higher costs or a higher cost per LYS than a more effective strategy. ◆
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The major components of the undiscounted costs over the life-
times of 2420 LS carriers associated with universal dMMR tumour 
testing in the Stage 1 (baseline) analysis were those for newly 
detected cancer treatment (range, $81 672 800–$82 555 200) and 
colonoscopic surveillance (range, $56 452 200–$57 350 400), with 
lower cost ranges for tumour testing ($2  815  080–$5  038  780), 
proband gene panel testing ($2 234 670–$6 353 170) and predic-
tive targeted gene testing for relatives ($2 163 910–$2 165 240). In 
the Stage 2 analysis, colonoscopic surveillance costs over the life-
times of 2420 LS carriers, with the same testing age cut- off, were 
lower with 2- yearly than with annual colonoscopic surveillance 
($8 815 020–$29 261 400) (Box 6).
For a given testing strategy and age limit, the number of life- 
years saved by annual colonoscopic surveillance was not sub-
stantially greater than with 2- yearly colonoscopic surveillance, 
but the costs were substantially higher, and the cost difference 
increased with rising age cut- off. Testing strategies including 
annual colonoscopic surveillance were consequently less cost- 
effective than those with 2- yearly surveillance (Box 4, B).
In the Stage 3 sensitivity analyses, the parameter with the great-
est influence on cost- effectiveness was the assumed impact of 
colonoscopic surveillance on CRC incidence; that is, colono-
scopic surveillance down- stages diagnosed cancers but does not 
reduce the incidence (Box 7).
Discussion
We have reported one of the most comprehensive evaluations un-
dertaken in any country of the cost- effectiveness of systematic test-
ing, cascade testing, and subsequent surveillance for LS. We found 
that all universal dMMR tumour testing strategies for people with 
incident CRC, without age limit and with annual colonoscopic 
5 Health and resource outcomes associated with testing people with incident colorectal cancer (CRC) diagnosed in Australia during 
2017 for Lynch syndrome (LS), compared with no testing (per 1000 people with incident CRC with LS and 1420 relatives with 
confirmed LS)
Testing strategy (age range for testing;  
colonoscopic surveillance interval)
Cases of 
cancer
Cancer 
deaths Colonoscopies
Cancer 
deaths 
averted
Colonoscopies 
to avert one 
death
Stage 1 analysis
1. No testing 1566 630 — — —
7. MSI + MLH1 methylation (no age limit; 1 year) 1248 446 30 597 184 166
6. MSI + BRAF V600E (no age limit; 1 year) 1246 445 30 697 185 166
5. MSI (no age limit; 1 year) 1243 442 30 865 187 165
4. IHC + MLH1 methylation (no age limit; 1 year) 1243 442 30 952 188 165
3. IHC + BRAF V600E (no age limit; 1 year) 1242 441 30 995 189 164
2. IHC (no age limit; 1 year) 1241 440 31 084 189 164
8. Universal gene panel testing (no age limit; 1 year) 1239 438 31 257 192 163
Stage 2 analysis
1. No testing 1566 630 — — —
3.3. IHC + BRAF V600E (< 50 years; 2 years) 1500 583 4778 46 103
3.2. IHC + BRAF V600E (< 50 years; 1 year) 1491 582 9457 48 198
8.3. Universal gene panel testing (< 50 years; 2 years) 1500 583 4837 47 103
8.2. Universal gene panel testing (< 50 years; 1 year) 1491 581 9571 49 196
3.5. IHC + BRAF V600E (< 60 years; 2 years) 1398 518 10 642 112 95
8.5. Universal gene panel testing (< 60 years; 2 years) 1396 516 10 756 114 94
3.4. IHC + BRAF V600E (< 60 years; 1 year) 1375 513 20 976 117 180
8.4. Universal gene panel testing (< 60 years; 1 year) 1374 511 21 197 119 179
3.7. IHC + BRAF V600E (< 70 years; 2 years) 1319 471 14 251 159 90
8.7. Universal gene panel testing (< 70 years; 2 years) 1317 468 14 383 161 89
3.6. IHC + BRAF V600E (< 70 years; 1 year) 1287 464 27 970 165 169
8.6. Universal gene panel testing (< 70 years; 1 year) 1284 462 28 226 168 168
3.1. IHC + BRAF V600E (no age limit; 2 years) 1279 449 15 860 181 88
8.1. Universal gene panel testing (no age limit; 2 years) 1275 446 15 999 184 87
3. IHC + BRAF V600E (no age limit; 1 year) 1242 441 30 995 189 164
8. Universal gene panel testing (no age limit; 1 year) 1239 438 31 257 192 163
IHC = immunohistochemistry; MSI = microsatellite instability. ◆
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6 Lifetime discounted costs associated with testing people with incident colorectal cancer (CRC) diagnosed in Australia during 2017 for 
Lynch syndrome (LS), compared with no testing (per 1000 people with incident CRC with LS and 1420 relatives with confirmed LS) 
Testing strategy (age range 
for testing; colonoscopic 
surveillance interval)
Cost (proportion of total cost)
Total costs
Proband gene 
panel testing
Relatives’ 
genetic 
testing and 
counselling
dMMR tumour 
testing
Cancer 
treatment* Colonoscopy
Stage 1 analysis
1. No testing $110 474 000 — — — $110 474 000 (100%) —
7. MSI + MLH1 methylation 
(no age limit; 1 year)
$148 479 000 $2 268 750 (2%) $2 163 910 (1%) $5 038 780 (3%) $82 555 200 (56%) $56 452 200 (38%)
6. MSI + BRAF V600E (no age 
limit; 1 year)
$148 412 000 $2 234 670 (2%) $2 165 240 (1%) $5 038 730 (3%) $82 338 100 (55%) $56 635 400 (38%)
5. MSI (no age limit; 1 year) $150 300 000 $6 353 170 (4%) $2 164 630 (1%) $2 815 080 (2%) $82 021 700 (55%) $56 945 300 (38%)
4. IHC + MLH1 methylation 
(no age limit; 1 year)
$148 225 000 $3 395 100 (2%) $2 164 830 (1%) $3 665 380 (2%) $81 892 700 (55%) $57 106 900 (39%)
3. IHC + BRAF V600E (no age 
limit; 1 year)
$148 193 000 $3 386 450 (2%) $2 164 670 (1%) $3 665 260 (2%) $81 789 600 (55%) $57 186 600 (39%)
2. IHC (no age limit; 1 year) $148 861 000 $4 858 440 (3%) $2 164 240 (1%) $2 815 080 (2%) $81 672 800 (55%) $57 350 400 (39%)
8. Universal gene panel test-
ing (no age limit; 1 year)
$175 199 000 $34 007 500 (19%) $2 164 360 (1%) — $81 357 600 (46%) $57 669 300 (33%)
Stage 2 analysis
1. No testing $110 474 000 — — — $110 474 000 (100%) —
3.3. IHC + BRAF V600E (< 50 
years; 2 years)
$114 170 000 $397 177 (< 1%) $459 442 (< 1%) $529 723 (< 1%) $103 969 000 (91%) $8 815 020 (8%)
3.2. IHC + BRAF V600E (< 50 
years; 1 year)
$122 399 000 $397 207 (< 1%) $459 183 (< 1%) $529 606 (< 1%) $103 565 000 (85%) $17 448 200 (14%)
8.3. Universal gene panel 
testing (< 50 years; 2 years)
$116 060 000 $2 737 630 (2%) $459 216 (< 1%) — $103 939 000 (90%) $8 924 350 (8%)
8.2. Universal gene panel 
testing (< 50 years; 1 year)
$124 294 000 $2 737 530 (2%) $459 167 (< 1%) — $103 439 000 (83%) $17 658 000 (14%)
3.5. IHC + BRAF V600E (< 60 
years; 2 years)
$117 501 000 $1 160 090 (1%) $1 176 740 (1%) $1 139 730 (1%) $94 389 500 (80%) $19 634 800 (17%)
8.5. Universal gene panel 
testing (< 60 years; 2 years)
$124 180 000 $9 014 050 (7%) $1 176 590 (1%) — $94 144 300 (76%) $19 844 700 (16%)
3.4. IHC + BRAF V600E (< 60 
years; 1 year)
$135 409 000 $1 160 100 (1%) $1 176 150 (1%) $1 139 690 (1%) $93 231 700 (69%) $38 701 300 (29%)
8.4. Universal gene panel 
testing (< 60 years; 1 year)
$142 286 000 $9 013 810 (6%) $1 176 350 (1%) — $92 987 300 (65%) $39 108 900 (27%)
3.7. IHC + BRAF V600E (< 70 
years; 2 years)
$119 303 000 $2 005 420 (2%) $1 791 260 (2%) $1 937 940 (2%) $87 275 300 (73%) $26 292 600 (22%)
8.7. Universal gene panel 
testing (< 70 years; 2 years)
$132 274 000 $17 064 300 (13%) $1 790 520 (1%) — $86 883 100 (66%) $26 536 500 (20%)
3.6. IHC + BRAF V600E (< 70 
years; 1 year)
$142 963 000 $2 005 540 (1%) $1 790 300 (1%) $1 937 960 (1%) $85 625 000 (60%) $51 604 400 (36%)
8.6. Universal gene panel 
testing (< 70 years; 1 year)
$156 170 000 $17 064 100 (11%) $1 790 140 (1%) — $85 239 800 (55%) $52 076 300 (33%)
3.1. IHC + BRAF V600E (no 
age limit; 2 years)
$122 173 000 $3 386 260 (3%) $2 165 780 (2%) $3 665 230 (3%) $83 693 900 (69%) $29 261 400 (24%)
8.1. Universal gene panel 
testing (no age limit; 2 
years)
$148 950 000 $34 007 900 (23%) $2 164 800 (1%) — $83 259 600 (56%) $29 517 400 (20%)
3. IHC + BRAF V600E (no age 
limit; 1 year)
$148 193 000 $3 386 450 (2%) $2 164 670 (1%) $3 665 260 (2%) $81 789 600 (55%) $57 186 600 (39%)
8. Universal gene panel  
testing (no age limit; 1 year)
$175 199 000 $34 007 500 (19%) $2 164 360 (1%) — $81 357 600 (46%) $57 669 300 (33%)
dMMR = DNA mismatch repair deficiency; IHC = immunohistochemistry; MSI = microsatellite instability. * Initial CRC treatment costs for the proband were not included in the analysis, as 
they were assumed to not be affected by LS testing. ◆
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surveillance of confirmed LS carriers, were similarly cost- effective 
(compared with no testing) at an indicative willingness- to- pay 
threshold of $30  000–$50  000/LYS; the most cost- effective strat-
egy was immunohistochemistry with reflex BRAF V600E testing. 
Universal dMMR tumour testing strategies could reduce the num-
ber of CRC deaths by 184–189 while increasing the number of colo-
noscopies by 30 597–31 084 over the lifetimes of 1000 people with 
CRC and LS and 1420 relatives confirmed to be LS carriers (164–166 
additional colonoscopies per death averted).
Our assumption that a mean six relatives per proband would 
be eligible for cascade genetic testing was probably conserva-
tive, and the benefits of systematic LS testing could therefore be 
greater than estimated. Life expectancy in Australia is compar-
atively high, which could also increase the cost- effectiveness of 
interventions, such as LS testing, that chiefly extend the longev-
ity of older people. Based on the number of people diagnosed 
with incident CRC in Australia (about 15 000 in 201414) and the 
estimated proportion of LS carriers (2.8%),22 about 420 probands 
could be identified per year, or 1000 probands over about 2.5 
years. Routine dMMR tumour testing could therefore avert 
as many as 80 CRC deaths per year, and would require 13 000 
extra colonoscopies per year, in addition to the 100 000–125 000 
colonoscopies generated by referrals and surveillance under the 
National Bowel Cancer Screening Program.16
7 One- way sensitivity analyses of the cost- effectiveness of Lynch syndrome (LS) testing (all ages, annual surveillance of confirmed LS 
carriers [probands and relatives]), compared with no testing*
CI = confidence interval; dMMR = mismatch repair deficiency; HR = hazard ratio; IHC = immunohistochemistry.* The change in cost- effectiveness associated with the first indicated value 
for a parameter is depicted by the darker (left side) bars, which indicate lower cost- effectiveness ratio (ie, more cost- effective), the change associated with the second value is depicted 
by the lighter (right side) bars, which indicate higher cost- effectiveness ratio (ie, less cost- effective).Solid vertical line: Stage 1 cost- effectiveness estimate; dotted vertical lines: indicative 
willingness- to- pay threshold $30 000–$50 000/life- year saved.For sensitivity and specificity of dMMR tumour testing, 95% CIs of pooled estimates for IHC, microsatellite instability, BRAF 
V600E, and MLH1 hypermethylation tests were varied simultaneously. ◆
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We found that 2- yearly colonoscopic surveillance was more 
cost- effective than annual surveillance, while assuming that 
CRC incidence is reduced a further 10% by annual surveillance 
compared with 2- yearly surveillance. Recent studies found no 
statistically significant differences by surveillance interval in 
cumulative CRC incidence or CRC stage at diagnosis in people 
with LS.23,24 Ongoing quality colonoscopy is required to maxi-
mise the benefits of any strategy. We also found that universal 
germline gene panel testing is not as cost- effective as dMMR test 
strategies, but its cost could decline substantially in the near fu-
ture. Were universal gene panel testing introduced, it is likely 
that dMMR tumour testing would still be employed in clini-
cal settings, both to guide treatment decisions for a subgroup 
of patients with dMMR tumours and to assist interpretation of 
genetic test results (eg, variants of uncertain significance). If fur-
ther evidence for the role of dMMR testing in guiding cancer 
treatment accrues, the cost- effectiveness of routine testing might 
require re- assessment.
Several factors determine which laboratory test is chosen for 
identifying dMMR and excluding somatic MMR mutations. 
Immunohistochemistry is more convenient because it can be 
semi- automated and performed in any histopathology labora-
tory, whereas microsatellite instability testing, which is more 
complicated, is available in fewer laboratories.25 BRAF V600E 
reflex testing for dMMR in tumour samples is appropriate only 
for samples from patients with CRC. MLH1 methylation testing 
is necessary when testing for LS in people with endometrial 
or other LS- related cancers; as MLH1 methylation testing is 
more complex, only some laboratories can perform it. In prac-
tice, the choice of universal dMMR and triage testing strategies 
will depend on local test availability and laboratory- specific 
considerations.
Limitations
We focused on life- years saved rather than quality- adjusted life- 
years because comprehensive data on health state preferences 
(ie, utilities) needed to calculate quality- adjusted life- years for 
people at risk of LS are not available. Although we assumed that 
gene panel testing is 100% sensitive (to simplify modelling), its 
reported sensitivity is 99.4%;18 that is, a very small proportion of 
LS carriers will not be detected. Further, we did not consider the 
impact of an incidental diagnosis (eg, non- LS hereditary cancers) 
following universal germline gene panel testing. As in earlier 
key analyses in the UK,10,11 we did not consider the possibility 
of systematic LS testing in the context of cancers at other sites 
(eg, endometrial cancer), nor did we consider the possible health 
benefits or likely harms and costs of gynaecological surveillance 
(eg, transvaginal ultrasound, aspiration biopsy) or prophylac-
tic surgery (eg, total abdominal hysterectomy with or without 
salpingo- oophorectomy) for women identified as LS carriers 
by systematic testing of people with CRC. However, there is no 
conclusive evidence for the effectiveness and health benefits of 
gynaecological surveillance. While we considered neither the 
health benefits of testing non- MMR genes nor endometrial can-
cer outcomes, we fully captured all downstream procedures, 
costs, and benefits involved in implementing a routine LS testing 
program for people with CRC. Our analysis accordingly comple-
ments the analysis of 11- gene panel testing currently underway.7
Conclusion
At an indicative willingness- to- pay threshold of $30  000–
$50  000/life- year saved, a range of universal dMMR tumour 
testing strategies for systematic LS testing of people with inci-
dent CRC are likely to be similarly cost- effective in Australia. 
Universal gene panel testing is not yet cost- effective, but should 
be re- evaluated should its costs drop, as is expected.
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